爱尔眼科1月9日大宗交易平台出现一笔成交，成交量22.10万股，成交金额249.95万元，大宗交易成交价 为11.31元，相对今日收盘价折价0.96%。该笔交易的买方营业部为华泰证券股份有限公司成都锦晖西二 街证券营业部，卖方营业部为华泰证券股份有限公司成都锦晖西二街证券营业部。 进一步统计，近3个月内该股累计发生7笔大宗交易，合计成交金额为7084.28万元。 | 成交量 | 成交金额 | 成交价 | 相对当日收盘 | | | | --- | --- | --- | --- | --- | --- | | （万 | （万元） | 格 | 折溢价（%） | 买方营业部 | 卖方营业部 | | 股） | | （元） | | | | | 22.10 | 249.95 | 11.31 | -0.96 | 华泰证券股份有限公司成 | 华泰证券股份有限公司成 | | | | | | 都锦晖西二街证券营业部 | 都锦晖西二街证券营业部 | （文章来源：证券时报网） 证券时报·数据宝统计显示，爱尔眼科今日收盘价为11.42元，上涨0.97%，日换手率为0.78%，成交额为 7.11亿元，全天主力资金净流入792.30万元， ...

证券日报网讯 1月8日，何氏眼科（301103）在互动平台回答投资者提问时表示，股价的波动受市场整 体情绪、行业板块轮动、资金偏好等多重因素综合影响。公司始终重视市值管理工作，坚持聚焦主业， 稳健经营，以投资者为本，通过不断完善公司治理、提升经营质量、合理规划现金分红、提高信息披露 和投资者关系管理水平，系统性推进市值管理工作，致力于实现公司内在价值与市场价值的动态平衡， 切实维护全体股东的长远利益。公司坚信，长期稳定的市值源于扎实的经营业绩与清晰的价值逻辑。未 来，公司坚持长期可持续发展战略、透明的信息披露与有效的投资者沟通，稳步推进资本市场品牌建 设，努力为投资者创造长期价值。 ...

证券日报网讯1月8日，何氏眼科（301103）在互动平台回答投资者提问时表示，公司管理层将根据公司 资金安排并结合实际经营情况及未来发展需求等多种因素考量，未来如有回购相关计划，将严格按照法 律法规及交易所规则，履行决策程序并及时披露相关信息。 ...

智通财经APP讯，朝聚眼科(02219)发布公告，于2026年1月8日，该公司斥资16.07万港元回购6万股。 ...

朝聚眼科(02219)发布公告，于2026年1月8日，该公司斥资16.07万港元回购6万股。 ...

格隆汇1月8日丨朝聚眼科(02219.HK)公告，1月8日耗资16万港元回购6万股，每股回购价2.66-2.69港 元。 ...

Core Viewpoint - The successful implementation of the EVO+ICL(V5) surgery at Shanghai Aier Eye Hospital marks a significant advancement in vision correction technology, particularly for individuals with high demands for night vision quality, offering a revolutionary "day and night high-definition" experience [1][8]. Group 1: Technology and Innovation - The EVO+ICL(V5) technology features an expanded optical zone design that effectively reduces night glare and halos, making it particularly suitable for individuals with high night vision requirements [2][4]. - The new ICL technology can correct a wide range of vision issues, accommodating myopia from 50 to 1400 degrees and astigmatism up to 600 degrees, while being reversible and not requiring corneal cutting [2][4]. - The EVO+ICL(V5) lens has an optical zone that expands to 7.6mm, significantly improving night vision by better covering the dark pupil [4]. Group 2: Material and Manufacturing - The lens is made from a unique Collamer material, which offers high biocompatibility, flexibility, effective UV blockage, and excellent long-term safety, ensuring a stable and lasting high-definition visual experience [5]. - The manufacturing process utilizes Swiss precision engineering, focusing on meticulous detail and continuous innovation to provide cutting-edge visual quality [6]. Group 3: Clinical Validation and Experience - The ICL technology has been validated through over 30 years of clinical practice, with more than 3 million lenses implanted globally across 75 countries, highlighting its reliability and acceptance among both doctors and patients [7]. - The successful surgery at Shanghai Aier Eye Hospital reflects the institution's strong technical capabilities, supported by a history of completing 550,000 ICL surgeries by 2025 and extensive experience in correcting high myopia and complex refractive errors [8][9]. Group 4: Future Directions - The hospital aims to continue introducing and applying globally leading technologies to meet the diverse and refined visual needs of urban residents, emphasizing a patient-centered approach in providing safe, precise, and clear vision correction solutions [9].

证券日报网讯1月7日，爱尔眼科（300015）在互动平台回答投资者提问时表示，公司专注眼科医疗，持 续关注前沿交叉学科的新进展。 ...

智通财经APP讯，朝聚眼科(02219)发布公告，联交所已于2026年1月6日授出新豁免，张光弟先生已获委 任为联席公司秘书，任期3年，自2026年1月7日起生效，而于上述变动后，罗伟健先生将继续担任另一 名联席公司秘书。 ...

Core Insights - The launch of the EVO+ICL(V5) project at Shenzhen Hima Lin Shun Chao Eye Hospital marks a significant advancement in refractive surgery technology in the Greater Bay Area, allowing local patients access to cutting-edge vision correction techniques [1][2] Group 1: Project Launch and Significance - The Shenzhen Hima Eye Hospital initiated the EVO+ICL(V5) project on January 7, 2023, following the first surgery on January 5, 2023, establishing a clinical application cooperation center and certifying surgeons [1][2] - The project is supported by strategic partnerships with leading global medical manufacturers, emphasizing the importance of international technology sharing for domestic healthcare [2][3] Group 2: Clinical Achievements and Future Plans - Shenzhen Hima Eye Hospital has performed over 10,000 ICL surgeries, showcasing its comprehensive refractive correction system and readiness for the new technology [3] - The hospital aims to implement strict operational standards and quality control systems to ensure the safe and precise application of the EVO+ICL(V5) technology [3] Group 3: Patient Experience and Technology Advantages - The first patient to undergo the EVO+ICL(V5) surgery reported significant improvements in vision quality, achieving a vision score of over 1.0 after the procedure [4] - The V5 technology offers four key advantages: larger optical zone design, improved night vision sensitivity, Swiss precision manufacturing, and over 30 years of clinical validation with more than 3 million implants globally [4]